Drug Name: 

DUPILUMAB*

Drug Description: 
IL-4R Antibody
Target Condition: 
Atopic dermatitis in pediatrics, asthma in pediatrics, chronic rhinosinusitis with nasal polyps (CRSwNP), eosinophilic esophagitis, chronic obstructive pulmonary disease (COPD)
Rank: 
25
Phase: 
Phase 3